INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing
INVO Fertility (NASDAQ: IVF) announced strategic enhancements to its INVOcell® technology program, including expanded clinical training support and improved pricing. INVOcell, the first FDA-cleared intravaginal culture system, offers a more natural fertility treatment alternative to traditional IVF with comparable pregnancy rates.
The company is strengthening its dual position as both a technology innovator and fertility clinic operator. Key features of INVOcell include using the woman's body as a natural incubator, demonstrated success rates comparable to conventional IVF, and increased accessibility for diverse family structures. The technology recently secured a new U.S. patent allowance and offers clinics improved operational efficiency.
INVO Fertility (NASDAQ: IVF) ha annunciato miglioramenti strategici al suo programma tecnologico INVOcell®, inclusi un supporto clinico ampliato e prezzi più vantaggiosi. INVOcell, il primo sistema di coltura intravaginale approvato dalla FDA, rappresenta un'alternativa più naturale al trattamento di fertilità tradizionale IVF, con tassi di gravidanza comparabili.
L'azienda sta rafforzando la sua duplice posizione di innovatore tecnologico e gestore di cliniche per la fertilità. Le caratteristiche principali di INVOcell includono l'utilizzo del corpo della donna come incubatrice naturale, tassi di successo dimostrati simili a quelli della IVF convenzionale e una maggiore accessibilità per diverse tipologie di famiglie. La tecnologia ha recentemente ottenuto un nuovo brevetto negli Stati Uniti e offre alle cliniche una migliore efficienza operativa.
INVO Fertility (NASDAQ: IVF) anunció mejoras estratégicas en su programa tecnológico INVOcell®, que incluyen un mayor apoyo en la formación clínica y precios mejorados. INVOcell, el primer sistema de cultivo intravaginal aprobado por la FDA, ofrece una alternativa de tratamiento de fertilidad más natural que la FIV tradicional, con tasas de embarazo comparables.
La empresa está fortaleciendo su doble rol como innovadora tecnológica y operadora de clínicas de fertilidad. Las características clave de INVOcell incluyen el uso del cuerpo de la mujer como incubadora natural, tasas de éxito similares a las de la FIV convencional y una mayor accesibilidad para diversas estructuras familiares. La tecnología recientemente obtuvo una nueva patente en EE.UU. y brinda a las clínicas una mayor eficiencia operativa.
INVO Fertility (NASDAQ: IVF)는 INVOcell® 기술 프로그램에 대한 전략적 개선 사항을 발표했으며, 임상 교육 지원 확대와 가격 개선을 포함합니다. INVOcell은 FDA 승인을 받은 최초의 질내 배양 시스템으로, 기존 IVF와 유사한 임신 성공률을 가지면서 더 자연스러운 생식 치료 대안을 제공합니다.
회사는 기술 혁신자이자 생식 클리닉 운영자로서의 이중 입지를 강화하고 있습니다. INVOcell의 주요 특징은 여성의 몸을 자연 인큐베이터로 활용하는 것, 기존 IVF와 비교할 만한 성공률, 다양한 가족 구조에 대한 접근성 향상입니다. 이 기술은 최근 미국에서 새로운 특허 허가를 받았으며 클리닉의 운영 효율성을 높여줍니다.
INVO Fertility (NASDAQ : IVF) a annoncé des améliorations stratégiques à son programme technologique INVOcell®, incluant un soutien clinique élargi et une tarification optimisée. INVOcell, le premier système de culture intravaginale approuvé par la FDA, propose une alternative plus naturelle au traitement de fertilité traditionnel par FIV, avec des taux de grossesse comparables.
L'entreprise renforce sa double position de pionnier technologique et d'opérateur de cliniques de fertilité. Les caractéristiques clés d'INVOcell comprennent l'utilisation du corps de la femme comme incubateur naturel, des taux de réussite similaires à ceux de la FIV conventionnelle, et une accessibilité accrue pour diverses structures familiales. La technologie a récemment obtenu un nouveau brevet aux États-Unis et offre aux cliniques une meilleure efficacité opérationnelle.
INVO Fertility (NASDAQ: IVF) hat strategische Verbesserungen seines INVOcell®-Technologieprogramms angekündigt, darunter erweiterte klinische Schulungsunterstützung und verbesserte Preisgestaltung. INVOcell, das erste von der FDA zugelassene intravaginale Kultursystem, bietet eine natürlichere Alternative zur herkömmlichen IVF mit vergleichbaren Schwangerschaftsraten.
Das Unternehmen stärkt seine doppelte Rolle als Technologieinnovator und Betreiber von Fruchtbarkeitskliniken. Zu den Hauptmerkmalen von INVOcell gehört die Nutzung des Körpers der Frau als natürlichen Inkubator, nachgewiesene Erfolgsraten, die mit der konventionellen IVF vergleichbar sind, sowie eine erhöhte Zugänglichkeit für verschiedene Familienstrukturen. Die Technologie erhielt kürzlich eine neue US-Patenterteilung und bietet Kliniken eine verbesserte Betriebseffizienz.
- INVOcell achieves pregnancy rates comparable to traditional IVF
- Recently secured new U.S. patent allowance for the technology
- Improved pricing structure to increase market accessibility
- Technology enables clinics to treat more patients within existing infrastructure
- None.
SARASOTA, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, today announced further efforts to drive its comprehensive strategy to enhance fertility services through expanded clinical and embryology training support and improved pricing for its innovative INVOcell® technology. This underscores the Company’s dual mission as an innovator of cutting-edge fertility solutions and a provider of compassionate, patient-centered clinical care through its established fertility clinics and is complementary to the Company’s focus on expanding its fertility clinic operations.
INVOcell is the world’s first FDA-cleared intravaginal culture (IVC) system, a patented medical device that enables fertilization and early embryo development to occur within a woman’s body, offering patients a more natural and intimate alternative to traditional in vitro fertilization (IVF). This innovative approach delivers comparable pregnancy rates to conventional IVF.
The Company offers training to embryologists and physicians, including hands-on instruction and clinical support to ensure seamless integration of the INVOcell solution into clinical practices. INVO Fertility also has introduced improved INVOcell pricing to make it even more affordable for patients and attractive to clinic operators. To boost general market awareness, INVO Fertility will also seek to launch targeted educational campaigns to highlight patient success rates which are similar to conventional IVF, as demonstrated by clinical studies and real-world patient outcomes.
“With our go-forward business focused exclusively on the fertility market, we are excited to renew our INVOcell efforts, in alignment with our mission to democratize fertility care,” said Steve Shum, CEO of INVO Fertility. “INVOcell represents a unique and innovative technology that, as recently announced, secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office. As both a technology innovator and a clinic service provider, INVO Fertility is positioned to deliver affordable, high-quality care through our clinics, while also empowering physicians with unique technology solutions.”
INVOcell offers:
- A more natural experience: by using the body as a real-life incubator, INVOcell provides a more intimate and emotionally connected journey for patients.
- Comparable success rates: clinical studies demonstrate that INVOcell achieves pregnancy rates similar to those of conventional IVF, as reflected in the independent reproductive technology data tracked by SART (the Society for Assisted Reproductive Technology).
- Inclusivity: the procedure is an excellent option for same-sex couples, single parents, and those seeking a less laboratory-intensive process.
- Efficiency for clinics: INVOcell provides a streamlined lab workflow, allowing clinics to easily integrate and treat additional patients within existing infrastructure.
Providers interested in INVOcell, seeking training or partnership opportunities can contact INVO Fertility at 941-321-2419, email bmitrovic@invobio.com or visit www.invocell.com.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (”ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
What is INVOcell and how does it differ from traditional IVF?
What are the success rates of INVO Fertility's (IVF) INVOcell treatment?
Who can benefit from INVO Fertility's (IVF) INVOcell treatment?
How does INVOcell benefit fertility clinics?
What support does INVO Fertility (IVF) provide for INVOcell implementation?
